Imirestat

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H326985

CAS#: 89391-50-4

Description: Imirestat, also known as AL-1576; AL-01576; Hoe-843, is an aldose reductase inhibitor potentially for the treatment of diabetes.

Chemical Structure

img
Imirestat
CAS# 89391-50-4
Instruction

Theoretical Analysis

Hodoodo Cat#: H326985
Name: Imirestat
CAS#: 89391-50-4
Chemical Formula: C15H8F2N2O2
Exact Mass: 286.06
Molecular Weight: 286.238
Elemental Analysis: C, 62.94; H, 2.82; F, 13.27; N, 9.79; O, 11.18

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Imirestat; AL-1576; AL-01576; Hoe-843; AL1576; AL01576; Hoe843.

IUPAC/Chemical Name: 2,7-Difluorospiro(fluorene-9,4'-imidazolidine)-2',5'-dione

InChi Key: QCCHBHSAIQIQGO-UHFFFAOYSA-N

InChi Code: InChI=1S/C15H8F2N2O2/c16-7-1-3-9-10-4-2-8(17)6-12(10)15(11(9)5-7)13(20)18-14(21)19-15/h1-6H,(H2,18,19,20,21)

SMILES Code: O=C1NC2(C(N1)=O)C3=C(C4=C2C=C(F)C=C4)C=CC(F)=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 286.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gilbert PJ, Hartley TE, Troke JA, Turcan RG, Vose CW, Watson KV. Application of 19F-n.m.r. spectroscopy to the identification of dog urinary metabolites of imirestat, a spirohydantoin aldose reductase inhibitor. Xenobiotica. 1992 Jul;22(7):775-87. PubMed PMID: 1455900.

2: Chien JY, Banfield CR, Brazzell RK, Mayer PR, Slattery JT. Saturable tissue binding and imirestat pharmacokinetics in rats. Pharm Res. 1992 Apr;9(4):469-73. PubMed PMID: 1495891.

3: Carrington AL, Ettlinger CB, Calcutt NA, Tomlinson DR. Aldose reductase inhibition with imirestat-effects on impulse conduction and insulin-stimulation of Na+/K(+)-adenosine triphosphatase activity in sciatic nerves of streptozotocin-diabetic rats. Diabetologia. 1991 Jun;34(6):397-401. PubMed PMID: 1653157.

4: McCue BA, Park YH, Brazzell RK, Boltralik JJ. Capillary gas chromatographic-electron-capture assay for the aldose reductase inhibitor imirestat in lens and plasma. J Chromatogr. 1991 Apr 19;565(1-2):255-64. PubMed PMID: 1908477.

5: Brazzell RK, Mayer PR, Dobbs R, McNamara PJ, Teng RL, Slattery JT. Dose-dependent pharmacokinetics of the aldose reductase inhibitor imirestat in man. Pharm Res. 1991 Jan;8(1):112-8. PubMed PMID: 1901647.

6: Vaidyanathan G, Jay M, Bera RK, Mayer PR, Brazzell RK. Scintigraphic evaluation of the ocular disposition of 18F-imirestat in rabbits. Pharm Res. 1990 Nov;7(11):1198-200. PubMed PMID: 2127314.

7: Brazzell RK, Wooldridge CB, Hackett RB, McCue BA. Pharmacokinetics of the aldose reductase inhibitor imirestat following topical ocular administration. Pharm Res. 1990 Feb;7(2):192-8. PubMed PMID: 2106677.

8: Pinkerton TC, Miller TD, Janis LJ. Effect of protein binding on the high-performance liquid chromatography of phenytoin and imirestat in human serum by direct injection onto internal surface reversed-phase columns. Anal Chem. 1989 May 15;61(10):1171-4. PubMed PMID: 2751110.